SNOA vs. AKBA

Last updated Apr 2, 2026

Compare and contrast key facts about Sonoma Pharmaceuticals, Inc. (SNOA) and Akebia Therapeutics, Inc. (AKBA).

Performance

SNOA vs. AKBA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sonoma Pharmaceuticals, Inc. (SNOA) and Akebia Therapeutics, Inc. (AKBA). The values are adjusted to include any dividend payments, if applicable.

SNOA vs. AKBA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SNOA Sonoma Pharmaceuticals, Inc.	-33.24%	35.32%	-25.44%	-83.89%	-75.44%	-37.19%	66.51%	-32.01%	-86.93%	8.13%
AKBA Akebia Therapeutics, Inc.	-12.42%	-15.26%	53.23%	114.90%	-74.47%	-19.29%	-55.70%	14.29%	-62.81%	42.84%

Fundamentals

Market Cap SNOA : $4.16M AKBA : $374.17M
EPS SNOA : -$2.02 AKBA : -$0.02
PS Ratio SNOA : 0.23 AKBA : 1.61
PB Ratio SNOA : 1.21 AKBA : 11.47
Total Revenue (TTM) SNOA : $17.72M AKBA : $236.19M
Gross Profit (TTM) SNOA : $6.76M AKBA : $196.73M
EBITDA (TTM) SNOA : -$3.06M AKBA : $19.26M

Returns By Period

In the year-to-date period, SNOA achieves a -33.24% return, which is significantly lower than AKBA's -12.42% return. Over the past 10 years, SNOA has underperformed AKBA with an annualized return of -44.24%, while AKBA has yielded a comparatively higher -17.19% annualized return.

SNOA

• 1D: 14.08%
• 1M: -14.44%
• YTD: -33.24%
• 6M: -37.05%
• 1Y: 11.98%
• 3Y*: -50.07%
• 5Y*: -57.54%
• 10Y*: -44.24%

AKBA

• 1D: 1.44%
• 1M: 11.90%
• YTD: -12.42%
• 6M: -47.39%
• 1Y: -26.18%
• 3Y*: 36.01%
• 5Y*: -15.79%
• 10Y*: -17.19%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SNOA vs. AKBA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SNOA

SNOA Risk / Return Rank: 52
SNOA Sharpe Ratio Rank: 43
SNOA Sortino Ratio Rank: 69
SNOA Omega Ratio Rank: 61
SNOA Calmar Ratio Rank: 44
SNOA Martin Ratio Rank: 44

AKBA

AKBA Risk / Return Rank: 27
AKBA Sharpe Ratio Rank: 24
AKBA Sortino Ratio Rank: 27
AKBA Omega Ratio Rank: 27
AKBA Calmar Ratio Rank: 28
AKBA Martin Ratio Rank: 30

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SNOA vs. AKBA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sonoma Pharmaceuticals, Inc. (SNOA) and Akebia Therapeutics, Inc. (AKBA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SNOA	AKBA	Difference
Sharpe ratio Return per unit of total volatility	0.10	-0.36	+0.47
Sortino ratio Return per unit of downside risk	1.57	-0.05	+1.62
Omega ratio Gain probability vs. loss probability	1.17	0.99	+0.17
Calmar ratio Return relative to maximum drawdown	0.18	-0.38	+0.56
Martin ratio Return relative to average drawdown	0.35	-0.62	+0.97
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SNOA vs. AKBA - Sharpe Ratio Comparison

The current SNOA Sharpe Ratio is 0.10, which is higher than the AKBA Sharpe Ratio of -0.36. The chart below compares the historical Sharpe Ratios of SNOA and AKBA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SNOA	AKBA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.10	-0.36	+0.47
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.49	-0.17	-0.32
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.43	-0.20	-0.23
Sharpe Ratio (All Time) Calculated using the full available price history	-0.33	-0.26	-0.07

Correlation

The correlation between SNOA and AKBA is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SNOA vs. AKBA - Dividend Comparison

Neither SNOA nor AKBA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

SNOA vs. AKBA - Drawdown Comparison

The maximum SNOA drawdown since its inception was -100.00%, roughly equal to the maximum AKBA drawdown of -99.14%. Use the drawdown chart below to compare losses from any high point for SNOA and AKBA.

Drawdown Indicators

	SNOA	AKBA	Difference
Max Drawdown Largest peak-to-trough decline	-100.00%	-99.14%	-0.86%
Max Drawdown (1Y) Largest decline over 1 year	-61.31%	-70.57%	+9.26%
Max Drawdown (5Y) Largest decline over 5 years	-98.97%	-94.05%	-4.92%
Max Drawdown (10Y) Largest decline over 10 years	-99.87%	-98.73%	-1.14%
Current Drawdown Current decline from peak	-100.00%	-95.17%	-4.83%
Average Drawdown Average peak-to-trough decline	-91.08%	-77.04%	-14.04%
Ulcer Index Depth and duration of drawdowns from previous peaks	31.52%	42.52%	-11.00%

Volatility

SNOA vs. AKBA - Volatility Comparison

Sonoma Pharmaceuticals, Inc. (SNOA) has a higher volatility of 25.98% compared to Akebia Therapeutics, Inc. (AKBA) at 14.87%. This indicates that SNOA's price experiences larger fluctuations and is considered to be riskier than AKBA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SNOA	AKBA	Difference
Volatility (1M) Calculated over the trailing 1-month period	25.98%	14.87%	+11.11%
Volatility (6M) Calculated over the trailing 6-month period	41.15%	60.07%	-18.92%
Volatility (1Y) Calculated over the trailing 1-year period	119.18%	72.07%	+47.11%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	117.80%	90.73%	+27.07%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	103.01%	84.10%	+18.91%

Financials

SNOA vs. AKBA - Profitability Comparison

The chart below illustrates the profitability comparison between Sonoma Pharmaceuticals, Inc. and Akebia Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

SNOA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Sonoma Pharmaceuticals, Inc. reported a gross profit of 1.65M and revenue of 4.35M. Therefore, the gross margin over that period was 37.9%.

AKBA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Akebia Therapeutics, Inc. reported a gross profit of 45.41M and revenue of 57.62M. Therefore, the gross margin over that period was 78.8%.

SNOA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Sonoma Pharmaceuticals, Inc. reported an operating income of -678.00K and revenue of 4.35M, resulting in an operating margin of -15.6%.

AKBA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Akebia Therapeutics, Inc. reported an operating income of -8.55M and revenue of 57.62M, resulting in an operating margin of -14.8%.

SNOA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Sonoma Pharmaceuticals, Inc. reported a net income of -819.00K and revenue of 4.35M, resulting in a net margin of -18.8%.

AKBA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Akebia Therapeutics, Inc. reported a net income of -12.24M and revenue of 57.62M, resulting in a net margin of -21.3%.